Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL.
Davies JR, Hilton LK, Jiang A, Barrans S, Burton C, Johnson PWM, Davies AJ, Du MQ, Tooze R, Cucco F, Care MA, Morin RD, Steidl C, Sha C, Westhead DR, Scott DW. Davies JR, et al. Among authors: barrans s. Blood Adv. 2023 Oct 24;7(20):6156-6162. doi: 10.1182/bloodadvances.2023010673. Blood Adv. 2023. PMID: 37595057 Free PMC article. No abstract available.
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, Kennedy H, Thompson JS, Uddin R, Worrillow L, Chalkley R, van Hoppe M, Ahmed S, Maishman T, Caddy J, Schuh A, Mamot C, Burton C, Tooze R, Davies A, Du MQ, Johnson PWM, Westhead DR. Sha C, et al. Among authors: barrans s. J Clin Oncol. 2019 Jan 20;37(3):202-212. doi: 10.1200/JCO.18.01314. Epub 2018 Dec 3. J Clin Oncol. 2019. PMID: 30523719 Free PMC article.
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
Cucco F, Barrans S, Sha C, Clipson A, Crouch S, Dobson R, Chen Z, Thompson JS, Care MA, Cummin T, Caddy J, Liu H, Robinson A, Schuh A, Fitzgibbon J, Painter D, Smith A, Roman E, Tooze R, Burton C, Davies AJ, Westhead DR, Johnson PWM, Du MQ. Cucco F, et al. Among authors: barrans s. Leukemia. 2020 May;34(5):1329-1341. doi: 10.1038/s41375-019-0691-6. Epub 2019 Dec 16. Leukemia. 2020. PMID: 31844144 Free PMC article.
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, Mamot C, Novak U, McMillan A, Fields P, Collins GP, Stephens R, Cucco F, Sha C, van Hoppe M, Tooze R, Davies JR, Griffiths G, Schuh A, Burton C, Westhead DR, Du MQ, Johnson PWM. Davies AJ, et al. Among authors: barrans s. J Clin Oncol. 2023 May 20;41(15):2718-2723. doi: 10.1200/JCO.23.00033. Epub 2023 Mar 27. J Clin Oncol. 2023. PMID: 36972491 Free PMC article. Clinical Trial.
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM. Davies A, et al. Among authors: barrans s. Lancet Oncol. 2019 May;20(5):649-662. doi: 10.1016/S1470-2045(18)30935-5. Epub 2019 Apr 1. Lancet Oncol. 2019. PMID: 30948276 Free PMC article. Clinical Trial.
68 results